Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.23)
# 403
Out of 5,242 analysts
234
Total ratings
64.2%
Success rate
9.48%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Overweight | $49 → $35 | $19.39 | +80.51% | 13 | May 14, 2026 | |
| CNC Centene | Maintains: Equal-Weight | $38 → $45 | $57.77 | -22.10% | 15 | Mar 4, 2026 | |
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $382.48 | +6.93% | 21 | Jan 23, 2026 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $158.86 | +16.45% | 23 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $255.75 | +19.65% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.46 | +34.05% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.56 | +114.84% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $22.14 | -66.12% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $16.37 | -26.67% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $193.82 | -25.19% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $181.26 | +101.37% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $766.50 | -45.21% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $7.91 | +1,417.07% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $303.68 | +104.16% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $389.82 | +28.26% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $93.32 | +32.88% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $282.02 | +12.76% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $200.61 | -65.11% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $168.02 | +16.06% | 6 | Oct 21, 2020 |
Doximity
May 14, 2026
Maintains: Overweight
Price Target: $49 → $35
Current: $19.39
Upside: +80.51%
Centene
Mar 4, 2026
Maintains: Equal-Weight
Price Target: $38 → $45
Current: $57.77
Upside: -22.10%
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $382.48
Upside: +6.93%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $158.86
Upside: +16.45%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $255.75
Upside: +19.65%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.46
Upside: +34.05%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.56
Upside: +114.84%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $22.14
Upside: -66.12%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $16.37
Upside: -26.67%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $193.82
Upside: -25.19%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $181.26
Upside: +101.37%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $766.50
Upside: -45.21%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $7.91
Upside: +1,417.07%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $303.68
Upside: +104.16%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $389.82
Upside: +28.26%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $93.32
Upside: +32.88%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $282.02
Upside: +12.76%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $200.61
Upside: -65.11%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $168.02
Upside: +16.06%